With Eli Lilly and Company and Novo Nordisk A/S releasing their third quarter financials on the same day, significant focus went to the developing competition in obesity between the two firms – already head-to-head rivals in diabetes for years – with one analyst saying Lilly’s Mounjaro (tirzepatide) is tracking ahead due to significant gross-to-net pricing advancement, even before the GLP-1/GIP agonist has obtained approval as a weight-loss treatment.
Both companies reported strong growth on 2 November for their competing products – Lilly’s Mounjaro, which is approved for type 2 diabetes and slated for potential US Food and Drug Administration approval in weight loss before year’s end, and Novo Nordisk’s GLP-1 agonist semaglutide, which is branded as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight loss
Key Takeaways
-
Lilly’s type 2 diabetes drug Mounjaro continued a heady launch, bringing in $1.4bn while awaiting FDA approval for weight loss.
-
Lilly is competing head-to-head with Novo Nordisk in diabetes while anticipating another head-to-head battle for Mounjaro versus Wegovy
